Amundi Pioneer Asset Management Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 44.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,907,512 shares of the company’s stock after selling 1,551,218 shares during the quarter. Amundi Pioneer Asset Management Inc.’s holdings in Zoetis were worth $315,693,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Peapack Gladstone Financial Corp lifted its holdings in shares of Zoetis by 7.4% during the third quarter. Peapack Gladstone Financial Corp now owns 3,790 shares of the company’s stock worth $627,000 after purchasing an additional 261 shares during the period. ExodusPoint Capital Management LP lifted its holdings in shares of Zoetis by 41.3% during the third quarter. ExodusPoint Capital Management LP now owns 5,232 shares of the company’s stock worth $865,000 after purchasing an additional 1,528 shares during the period. Eudaimonia Partners LLC lifted its holdings in shares of Zoetis by 130.3% during the third quarter. Eudaimonia Partners LLC now owns 1,803 shares of the company’s stock worth $298,000 after purchasing an additional 1,020 shares during the period. Intrua Financial LLC lifted its holdings in shares of Zoetis by 8.5% during the third quarter. Intrua Financial LLC now owns 2,056 shares of the company’s stock worth $341,000 after purchasing an additional 161 shares during the period. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Zoetis by 144.9% during the third quarter. Cubist Systematic Strategies LLC now owns 117,344 shares of the company’s stock worth $19,405,000 after purchasing an additional 69,438 shares during the period. 92.50% of the stock is owned by institutional investors and hedge funds.
Shares of ZTS stock opened at $157.88 on Thursday. Zoetis Inc. has a fifty-two week low of $121.50 and a fifty-two week high of $176.64. The stock has a market cap of $75.02 billion, a P/E ratio of 46.85, a P/E/G ratio of 4.35 and a beta of 0.71. The business has a fifty day simple moving average of $155.41 and a 200-day simple moving average of $160.68. The company has a quick ratio of 2.60, a current ratio of 3.47 and a debt-to-equity ratio of 2.41.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 1st. Investors of record on Wednesday, April 21st will be paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend is Tuesday, April 20th. Zoetis’s payout ratio is currently 27.47%.
In related news, EVP Robert Edward Kelly sold 2,055 shares of the stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $158.05, for a total transaction of $324,792.75. Also, Director Robert W. Scully acquired 7,590 shares of the firm’s stock in a transaction that occurred on Friday, February 19th. The shares were bought at an average cost of $164.68 per share, for a total transaction of $1,249,921.20. The disclosure for this purchase can be found here. 0.17% of the stock is owned by company insiders.
ZTS has been the subject of several recent research reports. Bank of America raised Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 price target for the company in a report on Monday, March 15th. Credit Suisse Group increased their price objective on Zoetis from $197.00 to $203.00 in a research report on Wednesday, February 17th. Finally, Raymond James upgraded Zoetis from a “market perform” rating to an “outperform” rating and set a $166.00 price objective for the company in a research report on Monday, March 15th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $170.08.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: What’s a Black Swan?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.